Treatment is always based on the best risk-benefit ratio for the patient, so stem cell therapy is reserved typically for patients who remain steroid dependent and whose disease remains active despite other more conventional therapies.
Unyango lusoloko lubhekiselele ekubeni lungakanani uncedo oluya kufunyanwa sisigulana xa luthelekiswa nobungozi bonyango, ngoko ke unyango lokufakelwa kweeseli zomzimba lulungiselelwe kuphela izigulana ezixhomekeke kwiisteroid nezinesifo esingadambiyo nkqu naxa zifumana olunye unyango oluqhelekileyo.